GICS Sector : Healthcare
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system.It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Insider Buying: Immunome (NASDAQ:IMNM) CEO Purchases $100,018.35 in Stock
Jan -02
Isaac Barchas Sells 383,200 Shares of Immunome (NASDAQ:IMNM) Stock
Dec -25
Immunome (NASDAQ:IMNM) CEO Clay Siegall Buys 7,278 Shares of Stock
Dec -23
Immunome: Maintaining "Strong Buy" On Successful RINGSIDE Trial With Varegacestat
Dec -17
Immunome Target of Unusually Large Options Trading (NASDAQ:IMNM)
Dec -16
Why Immunome Stock Surged Today
Dec -15
Why Immunome, A Top 3% Stock, Just Rocketed On Its Rivalry With Merck KGaA
Dec -15
Immunome's experimental drug meets main goal in late-stage study
Dec -15
Immunome, Inc.'s 10.55% growth in Biotechnology is driven by increasing demand for targeted therapies, advancements in gene editing technologies, and a strong pipeline of novel immunotherapies. Additionally, strategic partnerships and collaborations are fueling innovation and expanding market reach, contributing to the company's rapid growth.
IMM-101 is a therapeutic antibody cocktail designed to treat COVID-19. It is a combination of three antibodies that target the SARS-CoV-2 virus.
IMM-201 is a therapeutic antibody cocktail designed to treat cancer. It targets specific tumor-associated antigens and activates the immune system to fight cancer cells.
IMM-301 is a diagnostic platform that uses proprietary antibody-based technology to detect and diagnose infectious diseases, including COVID-19.
Immunome, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for cancer and infectious diseases.
Immunome, Inc. has a low bargaining power of customers due to the specialized nature of its products and services, which limits the ability of customers to negotiate prices.
Immunome, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and services, but the company's dependence on a few key suppliers for critical components.
Immunome, Inc. has a high threat of new entrants due to the attractiveness of the biotechnology industry and the potential for new companies to enter the market with innovative products and services.
Immunome, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among companies.
| Value | |
|---|---|
| Debt Weight | 1.36% |
| Debt Cost | 3.95% |
| Equity Weight | 98.64% |
| Equity Cost | 13.35% |
| WACC | 13.22% |
| Leverage | 1.38% |
Value: 0.2
Growth: 9.4
Quality: 7.9
Yield: 0.0
Momentum: 9.5
Volatility: 2.3
1-Year Total Return ->
Value: 6.0
Growth: 7.9
Quality: 4.7
Yield: 0.0
Momentum: 9.5
Volatility: 0.0
1-Year Total Return ->
Value: 6.2
Growth: 5.0
Quality: 4.4
Yield: 0.0
Momentum: 8.5
Volatility: 2.0
1-Year Total Return ->
Value: 6.2
Growth: 5.2
Quality: 4.7
Yield: 0.0
Momentum: 8.5
Volatility: 1.3
1-Year Total Return ->
Value: 4.5
Growth: 4.8
Quality: 4.7
Yield: 0.0
Momentum: 7.0
Volatility: 3.3
1-Year Total Return ->
Value: 6.4
Growth: 6.6
Quality: 3.9
Yield: 0.0
Momentum: 6.0
Volatility: 0.3
1-Year Total Return ->